HYSYSCO LTD.

Company number 08727464 ·

Active

This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.

Financial Health Assessment: HYSYSCO LTD.


1. Financial Health Score: B+

Explanation: HYSYSCO LTD. demonstrates fundamentally sound financial health with consistent profitability, strong liquidity, and a decade-long track record of building equity. However, the score is tempered by significant volatility in the balance sheet composition between 2023 and 2024, a dramatic shift in the debtor profile, and the limited transparency that comes with micro-entity filings. The underlying "vital signs" are healthy, but there are symptoms that warrant monitoring—much like a patient whose blood work shows overall wellness but with one or two anomalous readings that need investigation.


2. Key Vital Signs

Blood Pressure — Liquidity Ratios

Metric 2024 2023 Interpretation
Current Ratio 2.61 1.19 Healthy improvement; well above the 1.5 "normal" threshold
Cash Ratio 1.51 1.14 Strong; the company can cover current liabilities from cash alone
Net Current Assets £264,012 £166,805 Robust working capital position

Reading: The company's liquidity has strengthened considerably. In 2023, the current ratio of 1.19 was akin to "borderline high blood pressure"—functional but with little margin for error. By 2024, the ratio has improved to 2.61, indicating a comfortable ability to meet short-term obligations. The cash ratio of 1.51 means the business could settle all current liabilities twice over from cash reserves alone—a very healthy position.

Heart Rate — Profitability Indicators

Metric 2024 2023 Interpretation
Retained Earnings Growth £69,025 £- Consistent profit retention
Net Asset Growth 22.7% -10.8% Strong recovery and value creation
Shareholders' Funds £372,494 £303,469 Steady equity accumulation

Reading: The "heartbeat" of this business is strong. Retained earnings grew by £69,025 in 2024, indicating profitable trading. Looking at the longer history, the company has grown its equity from £60,501 at incorporation (2014) to £372,494—a cumulative build of over £312,000 in retained profits over a decade. This is the financial equivalent of a strong, steady pulse.

Cholesterol — Leverage and Debt Position

Metric 2024 2023 Interpretation
Debt-to-Equity Ratio 0.80 3.42 Dramatic improvement; leverage is now moderate
Long-term Liabilities £87,067 £98,592 Gradual reduction in long-term debt
Provisions £45,937 £47,790 Slight decrease; stable contingent liabilities

Reading: The 2023 debt-to-equity ratio of 3.42 was like dangerously high cholesterol—indicating the business was carrying significant obligations relative to its equity base. By 2024, this has normalized to 0.80, which is a healthy level. The reduction in current liabilities from £891,974 to £163,710 is the primary driver. Long-term liabilities have also been modestly reduced.

Body Temperature — Asset Composition

Asset Category 2024 2023 Change
Tangible Fixed Assets £241,486 £283,046 -14.7%
Debtors £180,472 £43,325 +316.6%
Cash £247,250 £1,015,454 -75.6%

Reading: This is where the "temperature" reading shows some irregularity. The asset base has undergone a dramatic restructuring:

  • Cash has fallen by £768,204 (75.6%), though it remains at a healthy absolute level
  • Debtors have increased by £137,147 (316.6%), suggesting either significant sales growth on credit terms or potential collection challenges
  • Fixed assets have decreased modestly, likely through depreciation

The shift from cash to debtors is the most notable feature of this year's accounts and warrants careful monitoring.


3. Diagnosis

Overall Financial Condition: Healthy with Symptoms Requiring Monitoring

Primary Diagnosis: The patient is in good overall health. HYSYSCO LTD. is a profitable, cash-generative manufacturing business that has built substantial equity over its 11-year life. The fundamental business model appears sound—manufacturing specialist machinery for the food and beverage sector provides consistent returns.

Symptom Analysis

Symptom 1: The 2023 Anomaly The 2023 balance sheet showed an extraordinary cash position of over £1 million alongside current liabilities of nearly £892,000. This pattern is consistent with one of several scenarios: - A large advance payment received from a customer before work commenced - Proceeds from a significant asset sale or insurance claim awaiting deployment - Timing of creditor payments (a large payable due shortly after the year-end)

By 2024, this has normalized—cash has reduced and current liabilities have decreased dramatically. This suggests the 2023 position was indeed temporary rather than structural.

Symptom 2: Rising Debtors The 316.6% increase in debtors from £43,325 to £180,472 is the most significant "red flag" in these accounts. This could indicate: - Positive interpretation: The business has grown significantly, taking on larger contracts with longer payment terms - Concerning interpretation: Customers are taking longer to pay, potentially straining working capital

Without revenue figures (which micro-entities are not required to disclose), it is difficult to determine which interpretation is correct. However, given that retained earnings grew by £69,025, revenue growth is the more likely explanation.

Symptom 3: Provisions The company carries £45,937 in provisions, which have been relatively stable over two years. These represent recognized but uncertain future obligations—like a dormant condition that hasn't worsened but hasn't resolved either. The nature of these provisions is not disclosed in micro-entity accounts.

Symptom 4: Minimal Share Capital With only £100 in share capital, the business has funded its growth almost entirely through retained profits. This is both a strength (demonstrating self-sufficiency) and a potential concern (limited buffer if trading conditions deteriorate).

Historical Health Trajectory

The long-term trend is encouraging:

Net Assets Progression: 2014: £60,501 ████ 2015: £163,401 ██████████ 2017: £283,196 ██████████████████ 2018: £285,561 ██████████████████ 2019: £240,371 ████████████████ 2020: £265,200 █████████████████ 2021: £150,171 ██████████ 2022: £339,407 ██████████████████████ 2023: £303,469 ████████████████████ 2024: £372,494 █████████████████████████

The dip in 2021 to £150,171 likely coincided with pandemic-related disruption in the manufacturing sector. The recovery since then has been strong, with net assets now at their highest level.


4. Prognosis

Future Financial Outlook: Cautiously Optimistic

Positive Factors: - Consistent profit generation over 11 years - Strong and improving liquidity position - Reducing leverage - Healthy cash reserves - Specialist manufacturing niche with likely recurring demand

Risk Factors: - Dependence on debtor collection (rising debtors as a proportion of current assets) - Limited visibility due to micro-entity filing status (no profit & loss account, no turnover disclosure) - Provisions of £45,937 representing uncertain future liabilities - Potential vulnerability to economic cycles in the food and beverage processing equipment sector

Outlook: Assuming the increase in debtors reflects genuine revenue growth rather than payment difficulties, the company is well-positioned for continued steady performance. The food processing machinery sector benefits from relatively stable demand. However, the business should guard against over-extending credit to customers, which could create a "cash flow blockage" similar to arterial restriction—profitable on paper but constrained in practice.


5. Recommendations

Immediate Actions (Next 3 Months)

  1. Debtor Health Check: Conduct an aged debtor analysis to understand the composition of the £180,472 owed. Identify any amounts overdue by more than 60 days and implement collection procedures. This is the single most important "preventative care" measure.

  2. Provision Review: Assess whether the £45,937 in provisions remains necessary and appropriately sized. If circumstances have changed, consider releasing unnecessary provisions to improve reported equity.

  3. Cash Management Strategy: With £247,250 in cash, evaluate whether surplus funds could be deployed more effectively—whether through investment in equipment, debt repayment, or short-term deposits to generate returns.

Medium-Term Actions (3-12 Months)

  1. Credit Control Policy: Formalize credit terms and collection procedures. The shift from £43,325 to £180,472 in debtors suggests the business may be extending more credit. Establish clear payment terms (e.g., 30 days) and follow up systematically.

  2. Long-term Liability Reduction: Continue the current trajectory of reducing long-term obligations (£98,592 → £87,067). Consider whether accelerated repayment would reduce interest costs and improve financial flexibility.

  3. Capital Investment Planning: Tangible fixed assets have decreased from £283,046 to £241,486, likely through depreciation. Assess whether the machinery and equipment base requires reinvestment to maintain competitive capability in food processing manufacturing.

Long-Term Strategic Considerations

  1. Succession and Governance: With three directors and two PSCs each owning 25-50%, the ownership structure could create decision-making challenges. Consider formalizing shareholder agreements and succession planning.

  2. Filing Status Review: As a micro-entity, HYSYSCO files minimal information. While this reduces administrative burden, it also limits transparency for stakeholders. As the company grows, consider whether filing as a small entity would provide more useful management information and enhance credibility with customers and suppliers.

  3. Revenue Diversification: Given the specialist nature of food processing machinery manufacturing, assess dependency on key customers or sectors. Diversification can provide "immunity" against sector-specific downturns.


Summary Dashboard

Vital Sign Status Trend
Liquidity ✅ Healthy Improving
Profitability ✅ Healthy Stable
Leverage ⚠️ Moderate Improving
Cash Position ✅ Healthy Declining but adequate
Debtor Quality

Perspective: Financial Health Diagnostician · Model: glm-5.1 · Generated 30 July 2026